{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:03:12Z","timestamp":1773954192809,"version":"3.50.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"abstract":"Abstract<\/jats:title>\n \n Objective:<\/jats:title>\n To determine whether the quantitative myasthenia gravis score (QMGS) accurately represents disease severity in patients with myasthenia gravis (MG).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n One hundred thirty-five patients with MG from 2 previous randomized studies were included. QMGS correlation with the Myasthenia Gravis Foundation of America (MGFA) score, quality of life scale, acetylcholine receptor antibodies (AChRAbs), and electrophysiological parameters was studied.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The QMGS showed a good correlation with the MGFA scale (r<\/jats:italic>\n 2<\/jats:sup> = 0.54, P<\/jats:italic> < 0.0001), jitter (r<\/jats:italic>\n s<\/jats:sub> = 0.40, P<\/jats:italic> < 0.0001), and 15-item quality of life scale (r<\/jats:italic>\n s<\/jats:sub> = 0.41, P<\/jats:italic> = 0.007) and was less well correlated with the 60-item myasthenia gravis\u2013specific quality of life survey and other electrophysiological markers. No correlation was demonstrated with AchRAb titers, but AchRAb-positive patients had higher QMGS (14.2 \u00b1 4.5) than AchRAb-negative patients (12.0 \u00b1 3.7, P<\/jats:italic> = 0.008).<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n These results demonstrate that the QMGS is a valid marker for disease severity as shown by the MGFA scale, quality of life scale, and jitter, supporting the use of the QMGS as a primary outcome measure in clinical trials of MG.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/cnd.0b013e31824619d5","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T11:50:46Z","timestamp":1337773846000},"page":"201-205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":55,"title":["The Quantitative Myasthenia Gravis Score"],"prefix":"10.1097","volume":"13","author":[{"given":"Carolina","family":"Barnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Katzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20240808","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":". Preliminary results of a double blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"R2-3-20240808","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":". Reliability testing of the quantitative myasthenia gravis score.","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"R3-3-20240808","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s004150050585","article-title":". Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis.","volume":"247","author":"Sharshar","year":"2000","journal-title":"J Neurol"},{"key":"R4-3-20240808","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":". Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"R5-3-20240808","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":". Myasthenia gravis: recommendations for clinical research standards.","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"R6-3-20240808","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"R7-3-20240808","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":". Comparison of IVIG and PLEX in patients with myasthenia gravis.","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"R8-3-20240808","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate with prednisone as initial immunotherapy in myasthenia gravis.","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"R9-3-20240808","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite. A valid and reliable outcome measure for myasthenia gravis.","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"R10-3-20240808","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"; and the Muscle Study Group. Disease specific measure of quality of life for myasthenia gravis.","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle Nerve"},{"key":"R11-3-20240808","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"; and the Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"R12-3-20240808","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1254.057","article-title":"A simple manual muscle test for myasthenia gravis. Validation and comparison with the QMGS score.","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R13-3-20240808","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.20908","article-title":"Surrogate therapeutic outcome measures in patients with myasthenia gravis.","volume":"37","author":"Zinman","year":"2008","journal-title":"Muscle Nerve"},{"key":"R14-3-20240808","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1212\/WNL.38.4.514","article-title":". Seronegative myasthenia gravis.","volume":"38","author":"Soliven","year":"1988","journal-title":"Neurology"},{"key":"R15-3-20240808","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1196\/annals.1405.020","article-title":". Myasthenia gravis seronegative for acetylcholine receptor antibodies.","volume":"1132","author":"Vincent","year":"2008","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00131402-201206000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:22:37Z","timestamp":1723159357000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00131402-201206000-00003"}},"subtitle":["Comparison With Clinical, Electrophysiological, and Laboratory Markers"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0b013e31824619d5","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}